These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 18178609

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.
    Koek GH, Sifrim D, Lerut T, Janssens J, Tack J.
    Gut; 2008 Aug; 57(8):1056-64. PubMed ID: 18403496
    [Abstract] [Full Text] [Related]

  • 3. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB, Boparai V, Ullah N, Triadafilopoulos G.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):637-43. PubMed ID: 15352912
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?
    Stoltey J, Reeba H, Ullah N, Sabhaie P, Gerson L.
    Aliment Pharmacol Ther; 2007 Jan 01; 25(1):83-91. PubMed ID: 17229223
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M, Manno M, De Micheli E, Savarino V.
    Dig Liver Dis; 2006 Sep 01; 38(9):643-8. PubMed ID: 16627016
    [Abstract] [Full Text] [Related]

  • 12. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
    Quera R, O'Sullivan K, Quigley EM.
    Endoscopy; 2006 Feb 01; 38(2):162-9. PubMed ID: 16479424
    [Abstract] [Full Text] [Related]

  • 13. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M, Green C, Faybush EM, Esquivel RF, Fass R.
    Aliment Pharmacol Ther; 2006 Jan 15; 23(2):321-9. PubMed ID: 16393313
    [Abstract] [Full Text] [Related]

  • 14. Barrett's oesophagus: a clinical study of 52 patients.
    Cooper BT, Barbezat GO.
    Q J Med; 1987 Feb 15; 62(238):97-108. PubMed ID: 3498962
    [Abstract] [Full Text] [Related]

  • 15. Adipocytokines and breast cancer risk.
    Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL, Sun Y, Wu Q, Chen L.
    Chin Med J (Engl); 2007 Sep 20; 120(18):1592-6. PubMed ID: 17908478
    [Abstract] [Full Text] [Related]

  • 16. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL, Ogunwobi O, Cameron E, El-Amin K, Mutungi G, Wilkinson M.
    BMC Cancer; 2007 Jun 08; 7():97. PubMed ID: 17559672
    [Abstract] [Full Text] [Related]

  • 17. Cytokeratin 7 and 20 expression in intestinal metaplasia of the distal oesophagus: relationship to gastro-oesophageal reflux disease.
    Shearer C, Going J, Neilson L, Mackay C, Stuart RC.
    Histopathology; 2005 Sep 08; 47(3):268-75. PubMed ID: 16115227
    [Abstract] [Full Text] [Related]

  • 18. Barrett's esophagus and medications that relax the lower esophageal sphincter.
    Corley DA, Levin TR, Habel LA, Buffler PA.
    Am J Gastroenterol; 2006 May 08; 101(5):937-44. PubMed ID: 16573773
    [Abstract] [Full Text] [Related]

  • 19. [Quantification of gastro-esophageal reflux in Barrett's esophagus].
    Ortiz Escandell A, Martínez de Haro LF, Parrilla Paricio P, Molina Martínez J, Aguayo Albasini JL, Martínez Gómez D.
    Rev Esp Enferm Dig; 1990 Mar 08; 77(3):171-5. PubMed ID: 2378753
    [Abstract] [Full Text] [Related]

  • 20. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
    Tsibouris P, Hendrickse MT, Isaacs PE.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):645-55. PubMed ID: 15352913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.